Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydros
- Development stage
- Discontinued
- Lead developer
- KalVista Pharmaceuticals
- Administration
- Intraarticular
01
Overview
Hydros is a clinical-stage, single-injection intra-articular viscosupplement developed by Carbylan Therapeutics for the treatment of pain associated with osteoarthritis of the knee. It consists of a bioresorbable, chemically cross-linked hyaluronic acid-based hydrogel suspended in a hyaluronic acid solution. Hydros is designed to restore the viscoelastic properties of the synovial fluid, providing mechanical cushioning and lubrication to the joint to relieve pain and improve mobility. Although evaluated in Phase 2 and Phase 3 clinical trials, further development of Hydros and its corticosteroid-loaded counterpart, Hydros-TA, was suspended in 2016 following mixed Phase 3 results.
- Brand names
- Hydros
- Other names
- hyaluronan-based hydrogel
Beyond the preview
Go deeper on Hydros.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hydros.